Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
Shionogi said on July 19 that it has kicked off a Japanese clinical trial for its COVID-19 vaccine S-268019 in children aged five through 11.The Osaka-based drug maker launched Part 1 of the PI/II/III trial, which is designed to gauge…
To read the full story
Related Article
- Shionogi Commences New COVID Vaccine Trials for Children
January 18, 2023
- Shionogi Delays Filing Plan for COVID-19 Vaccine to “By End of 2022”
October 13, 2022
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
- Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
- Secure Domestic Supply of Oral COVID-19 Med: Komeito to Govt
September 27, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
- All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
August 25, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
BUSINESS
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
- MM Drug Talquetamab Filed in Japan: J&J
November 21, 2024
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Otsuka Plans US Filing of IgA Nephropathy Drug in H1 2025
November 20, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…